Biosion, a clinical-stage biotechnology company with operations in Delaware, U.S., and China, has announced key findings from its Phase II proof-of-concept (POC) ADAMANT study for bosakitug, a candidate in its pipeline for the treatment of atopic dermatitis (AD). Bosakitug is a monoclonal antibody (mAb) that targets thymic stromal lymphopoietin (TSLP), a cytokine that plays a significant role in the pathogenesis of AD, asthma, and other eosinophil and Th2 immune-related diseases.
The study protocol involved all subjects receiving a weekly induction dose of 300mg for the initial 4 weeks, followed by maintenance doses of 300mg every two weeks, totaling 10 administrations. The results were impressive, with 94%, 69%, and 25% of participants achieving EASI (Eczema Area and Severity Index) scores of 75, 90, and 100, respectively, at 25 weeks (indicating a minimum 75%, 90%, or 100% improvement from baseline). Additionally, the investigator global assessment (IGA) score of 0/1, which signifies complete or near-complete clearance of lesions, was achieved by 94% of the participants. All subjects maintained an EASI 75 compliance even 12 weeks after their final administration.- Flcube.com
